Nephrotoxicity of rapamycin: An emerging problem in clinical medicine

Nephrology Dialysis Transplantation

Volumn 20, Issue 1, 2005, Pages 13-15

  Marti, Hans Peter ^a   Frey, Felix J ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Cyclosporine; Everolimus; Nephrotoxicity; Rapamycin; Renal allograft; Sirolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; EVEROLIMUS; RAPAMYCIN; TACROLIMUS;

APOPTOSIS; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG RESPONSE; GRAFT SURVIVAL; HIGH RISK POPULATION; HUMAN; KIDNEY ALLOGRAFT REJECTION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MAXIMUM TOLERATED DOSE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SIROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 13444274886     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh639     Document Type: Article

References (25)

1. Smith KD, Wrenshall LE, Nicosia RF et al. Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use. J Am Soc Nephrol 2003; 14: 1037-1045
2. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076
3. Morales JM, Wramner L, Kreis H et al. for the Sirolimus European Renal Transplant Study Group. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442
4. Formica RN, Lorber AM, Friedman AL et al. The evolving experience using everolimus in clinical transplantation. Transplant Proc 2004; 36 [Suppl 2S]: 495S-499S
5. Augustine JJ, Hricik DE. Experience with everolimus. Transplant Proc 2004; 36 [Suppl 1]: S500-S503
6. Crew RJ, Radhakrishnan J, Cohen D et al. De novo thrombotic microangiopathy following treatment with sirolimus: report of 2 cases. Nephrol Dial Transplant 2005; 20: 203-209
7. Kahan BD. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003; 35 [Suppl 3A]: 37S-51S
8. Lo A, Egidi MF, Gaber LW et al. Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation. Clin Transplant 2004; 18: 53-61
9. Lawsin L, Light JA. Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. Transplantation 2003; 75: 157-160
10. McTaggart RA, Gottlieb D, Brooks J et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416-423
11. Eisen HJ, Tuzcu EM, Dorent R et al. for the RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858
12. Fervenza FC, Fitzpatrick PM, Mertz J et al. for the Mayo Nephrology Collaborative Group. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004; 19: 1288-1292
13. Dittrich E, Schmaldienst S, Soleiman A, Horl WH, Pohanka E. Rapamycin-associated post-transplantation glomerulonephritis and its remission after reintroduction of calcineurin-inhibitor therapy. Transplant Int 2004; 17: 215-220
14. Schmelzle T, Hall MN. TOR a central controller of cell growth. Cell 2000; 103: 253-262
15. Lieberthal W, Fuhro R, Andry CC et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: F693-F706
16. Marx SO, Jayaraman T, Go LO, Marks AR. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995: 76: 412-417
17. Koh JS, Lieberthal W, Heydrick S, Levine JS. Lysophosphatidic acid is a major serum noncytokine survival factor for murine macrophages which acts via the phosphatidylinositol 3-kinase signaling pathway. J Clin Invest 1998; 102: 716-727
18. Andoh TF, Burdmann EA, Fransechini N, Houghton DC. Bennett WM. Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506. Kidney Int 1996; 50: 1110-1117
19. Daniel C, Ziswiler R, Frey B, Pfister M, Marti HP. Proinflammatory effects in experimental mesangial proliferative glomerulonephritis of the immunosuppressive agent SDZ RAD, a rapamycin derivative. Exp Nephrol 2000; 8: 52-62
20. KIP1. Lab Invest 2004; 84: 588-596
21. Podder H, Stepkowski SM, Napoli KM et al. Pharmacokinetic interactions augment toxicities of sirolimus-cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059-1071
22. Miller DS, Fricker G, Drewe J. p-Glycoprotein-rnediated transport of a fluorescent rapamycin derivative in renal proximal tubule. J Pharmacol Exp Ther 1997; 282: 440-444
23. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents: efficacy, side effects, and utilization. Pediatr Clin N Am 2003; 50: 1283-1300
24. MacDonald AS. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 2003; 35 [Suppl 3A]: 201S-208S
25. Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int 2001; 59: 3-16